Uveal Melanoma Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Novartis, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., AstraZeneca, IDEAYA Biosciences, Ve

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Uveal Melanoma pipeline constitutes 25+ key companies continuously working towards developing 30+ Uveal Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Uveal Melanoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uveal Melanoma Market.

The Uveal Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Uveal Melanoma Pipeline Report: https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Uveal Melanoma treatment therapies with a considerable amount of success over the years.
• Uveal Melanoma companies working in the treatment market are IDEAYA Biosciences, Verastem, Inc., Pfizer, Acrotech Biopharma Inc., Bristol-Myers Squibb, Iovance Biotherapeutics, Inc., Modulation Therapeutics, Inc., BioMed Valley Discoveries, Inc, Bellicum Pharmaceuticals, Merck Sharp & Dohme LLC, Eisai Inc., Delcath Systems Inc., Vanquish Oncology, Inc., Novartis, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., AstraZeneca, and others, are developing therapies for the Uveal Melanoma treatment
• Emerging Uveal Melanoma therapies in the different phases of clinical trials are- IDE196, VS-6766, Binimetinib + Belinostat, Ipilimumab and Nivolumab, Nivolumab + Relatlimab, Lifileucel (LN-144), microCi 225Ac-MTI-201, BVD-523, BPX-701, Pembrolizumab + Lenvatinib, Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS), PAC-1 and Entrectinib, DYP688, FHD-286, SD-101, Olaparib, and others are expected to have a significant impact on the Uveal Melanoma market in the coming years.
• In August 2023, IDEAYA Biosciences has initiated a Phase 2/3 study, DAR-UM-2, exploring IDE196 (Darovasertib) in combination with crizotinib versus the investigator's chosen treatment as the primary therapeutic approach for metastatic uveal melanoma (MUM) in participants negative for human leukocyte antigen (HLA)-A*02:01. This open-label, multi-arm, multi-stage study involves randomizing HLA-A2 negative individuals with MUM to receive either IDE196 + crizotinib or the investigator's selected treatment, which includes options such as pembrolizumab, ipilimumab + nivolumab, or dacarbazine.
• In May 2023, IDEAYA Biosciences has revised its clinical trial collaboration and supply agreements with Pfizer Inc., aiming to facilitate the assessment of the combination therapy involving darovasertib and crizotinib in the planned Phase 2/3 registrational clinical trial for metastatic uveal melanoma (MUM). The amendments also extend support for IDEAYA's ongoing Phase 2 clinical trial in MUM.
• In May 2022, IDEAYA Biosciences revealed that the US Food and Drug Administration (FDA) has bestowed orphan drug designation upon darovasertib. This promising compound, a potential first-in-class protein kinase C (PKC) inhibitor, is intended for the treatment of uveal melanoma.
• Emerging uveal melanoma pipeline therapies encompass Melphalan, AU-011 (bezupacap sarotalocan), SEA-CD40, IDE 196 (darovasertib), LNS8801, APG-115, Dacarbazine, and several others with potential.

Uveal Melanoma Overview
Uveal melanoma is a type of cancer that occurs in the uvea, which is the middle layer of the eye. The uvea consists of the iris (colored part of the eye), the ciliary body (a ring of tissue behind the iris), and the choroid (a layer of blood vessels that nourishes the retina).

Get a Free Sample PDF Report to know more about Uveal Melanoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Uveal Melanoma Drugs Under Different Phases of Clinical Development Include:
• IDE196: IDEAYA Biosciences
• VS-6766: Verastem, Inc.
• Binimetinib + Belinostat: Pfizer/Acrotech Biopharma Inc.
• Ipilimumab and Nivolumab: Bristol-Myers Squibb
• Nivolumab + Relatlimab: Bristol-Myers Squibb
• Lifileucel (LN-144): Iovance Biotherapeutics, Inc.
• microCi 225Ac-MTI-201: Modulation Therapeutics, Inc.
• BVD-523: BioMed Valley Discoveries, Inc
• BPX-701: Bellicum Pharmaceuticals
• Pembrolizumab + Lenvatinib: Merck Sharp & Dohme LLC/Eisai Inc.
• Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS): Delcath Systems Inc.
• PAC-1 and Entrectinib: Vanquish Oncology, Inc.
• DYP688: Novartis
• FHD-286: Foghorn Therapeutics Inc.
• SD-101: TriSalus Life Sciences, Inc.
• Olaparib: AstraZeneca

Uveal Melanoma Route of Administration
Uveal Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Subcutaneous
• Intravenous
• Intramuscular

Uveal Melanoma Molecule Type
Uveal Melanoma Products have been categorized under various Molecule types, such as
• Bispecific Antibody
• Peptides
• Small molecule
• Gene therapy

Uveal Melanoma Pipeline Therapeutics Assessment
• Uveal Melanoma Assessment by Product Type
• Uveal Melanoma By Stage and Product Type
• Uveal Melanoma Assessment by Route of Administration
• Uveal Melanoma By Stage and Route of Administration
• Uveal Melanoma Assessment by Molecule Type
• Uveal Melanoma by Stage and Molecule Type
DelveInsight's Uveal Melanoma Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Uveal Melanoma product details are provided in the report. Download the Uveal Melanoma pipeline report to learn more about the emerging Uveal Melanoma therapies at:
https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Uveal Melanoma Therapeutics Market include:
Key companies developing therapies for Uveal Melanoma are - Novartis, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., AstraZeneca, IDEAYA Biosciences, Verastem, Inc., Pfizer, Acrotech Biopharma Inc., Bristol-Myers Squibb, Iovance Biotherapeutics, Inc., Modulation Therapeutics, Inc., BioMed Valley Discoveries, Inc, Bellicum Pharmaceuticals, Merck Sharp & Dohme LLC, Eisai Inc., Delcath Systems Inc., Vanquish Oncology, Inc., and others.

Uveal Melanoma Pipeline Analysis:
The Uveal Melanoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Uveal Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uveal Melanoma Treatment.
• Uveal Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uveal Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uveal Melanoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Uveal Melanoma drugs and therapies-
https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Uveal Melanoma Pipeline Market Drivers
• Increasing Prevalence of the eye cancer, increase in research and developmental activities are some of the important factors that are fueling the Uveal Melanoma Market.

Uveal Melanoma Pipeline Market Barriers
• However, high-cost associated with the disease, lack of awareness about the disease and other factors are creating obstacles in the Uveal Melanoma Market growth.

Scope of Uveal Melanoma Pipeline Drug Insight
• Coverage: Global
• Key Uveal Melanoma Companies: IDEAYA Biosciences, Verastem, Inc., Pfizer, Acrotech Biopharma Inc., Bristol-Myers Squibb, Iovance Biotherapeutics, Inc., Modulation Therapeutics, Inc., BioMed Valley Discoveries, Inc, Bellicum Pharmaceuticals, Merck Sharp & Dohme LLC, Eisai Inc., Delcath Systems Inc., Vanquish Oncology, Inc., Novartis, Foghorn Therapeutics Inc., TriSalus Life Sciences, Inc., AstraZeneca, and others
• Key Uveal Melanoma Therapies: IDE196, VS-6766, Binimetinib + Belinostat, Ipilimumab and Nivolumab, Nivolumab + Relatlimab, Lifileucel (LN-144), microCi 225Ac-MTI-201, BVD-523, BPX-701, Pembrolizumab + Lenvatinib, Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS), PAC-1 and Entrectinib, DYP688, FHD-286, SD-101, Olaparib, and others
• Uveal Melanoma Therapeutic Assessment: Uveal Melanoma current marketed and Uveal Melanoma emerging therapies
• Uveal Melanoma Market Dynamics: Uveal Melanoma market drivers and Uveal Melanoma market barriers

Request for Sample PDF Report for Uveal Melanoma Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/uveal-melanoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Uveal Melanoma Report Introduction
2. Uveal Melanoma Executive Summary
3. Uveal Melanoma Overview
4. Uveal Melanoma- Analytical Perspective In-depth Commercial Assessment
5. Uveal Melanoma Pipeline Therapeutics
6. Uveal Melanoma Late Stage Products (Phase II/III)
7. Uveal Melanoma Mid Stage Products (Phase II)
8. Uveal Melanoma Early Stage Products (Phase I)
9. Uveal Melanoma Preclinical Stage Products
10. Uveal Melanoma Therapeutics Assessment
11. Uveal Melanoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Uveal Melanoma Key Companies
14. Uveal Melanoma Key Products
15. Uveal Melanoma Unmet Needs
16 . Uveal Melanoma Market Drivers and Barriers
17. Uveal Melanoma Future Perspectives and Conclusion
18. Uveal Melanoma Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Uveal Melanoma Market https://www.delveinsight.com/report-store/uveal-melanoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Uveal MelanomaMarket Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Uveal Melanoma Epidemiology https://www.delveinsight.com/report-store/uveal-melanoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Uveal Melanoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2028 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2028 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2028 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.